Founded in 2015 by a team responsible for the FDA’s approval of the world’s first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies. Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.
Type
Private
HQ
Seattle, US
Founded
2015
Alpine Immune Sciences was founded in 2015 and is headquartered in Seattle, US
Report incorrect company information

Key People/Management at Alpine Immune Sciences

Mitchell H. Gold

Mitchell H. Gold

Executive Chairman & CEO
Mark Litton

Mark Litton

President & Chief Operating Officer
Stanford Peng

Stanford Peng

Executive VP of R&D, Chief Medical Officer
Kristine Swiderek

Kristine Swiderek

Senior VP of Research
Paul Rickey

Paul Rickey

CFO
Show more

Alpine Immune Sciences Office Locations

Alpine Immune Sciences has an office in Seattle
Seattle, US (HQ)
200 Elliott Avenue West
Show all (1)
Report incorrect company information

Alpine Immune Sciences Financials and Metrics

Summary Metrics

Founding Date

2015

Alpine Immune Sciences total Funding

$49.3 m

Alpine Immune Sciences latest funding size

$48 m

Time since last funding

2 years ago

Alpine Immune Sciences investors

Alpine Immune Sciences's latest funding round in June 2016 was reported to be $48 m. In total, Alpine Immune Sciences has raised $49.3 m
Show all financial metrics

Alpine Immune Sciences Revenue

Alpine Immune Sciences's revenue was reported to be $1.73 m in FY, 2017 which is a 41.3% decrease from the previous period.
USD

EBIT (Q2, 2018)

(14 m)

Cash (30-Jun-2018)

3.6 m
USDFY, 2015FY, 2016FY, 2017

Revenue

492 k3 m1.7 m

Revenue growth, %

500%(41%)

General and administrative expense

441 k1.1 m6.1 m

R&D expense

422 k3 m10.6 m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

25 m11.8 m8 m

Prepaid Expenses

432 k36 k1.3 m

Current Assets

87.7 m11.9 m82.5 m

PP&E

223 k740 k1.1 m
Quarterly
USDQ2, 2018

Cash

3.6 m

Current Assets

71.8 m

PP&E

1.2 m

Total Assets

73.1 m
USDQ2, 2018

Net Income

(13.2 m)

Depreciation and Amortization

170 k

Accounts Payable

557 k

Cash From Operating Activities

(11.6 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Alpine Immune Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Alpine Immune Sciences Company Life and Culture

Report incorrect company information